Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
——
Precigen logo
PrecigenPGEN
——
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
——

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's proceeds from sale and maturity of available for sale securities?
BioCryst Pharmaceuticals (BCRX) reported proceeds from sale and maturity of available for sale securities of $221.24M in Q1 2026.
How has BioCryst Pharmaceuticals's proceeds from sale and maturity of available for sale securities changed year-over-year?
BioCryst Pharmaceuticals's proceeds from sale and maturity of available for sale securities increased by 191.1% year-over-year, from $76M to $221.24M.
What is the long-term trend for BioCryst Pharmaceuticals's proceeds from sale and maturity of available for sale securities?
Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's proceeds from sale and maturity of available for sale securities has grown at a 73.7% compound annual growth rate (CAGR), from $28.2M to $256.65M.